RECEPTA Biopharma
Recepta Biopharma is a Brazilian biotechnology company dedicated to research and development of new drugs for cancer treatment. Founded in 2006 through a partnership with the Ludwig Cancer Research Institute, the company focuses on developing monoclonal antibodies and peptides with potential therapeutic applications in oncology. Recepta Biopharma aims to provide innovative and affordable cancer treatments for the Brazilian population, leveraging Brazil's scientific and technological advantages in biopharmaceutical development. The company has a proven capacity to establish and successfully manage alliances and partnerships with various agents in the pharmaceutical sector, both private and public. Its mission is to discover new molecules, develop, and conduct clinical trials with monoclonal antibodies and peptides to offer more effective cancer treatment options with fewer side effects, using Brazil's scientific expertise to innovate and export high-value technology, contributing to reducing social and economic costs caused by cancer.
Industries
Nr. of Employees
small (1-50)
RECEPTA Biopharma
Rua Viradouro, 63. Conj.: 141. Sala 09, CEP: 04538-110, Itaim Bibi, São Paulo - SP, Brazil
Patents
Immunomodulatory peptides and methods for modulating the immune system in a subject
US-11479604-B2
View DetailsAntitumor peptide derived from a complementarity determining region of a humanized monoclonal antibody to NAP12B transporter
US-9896512-B2
View DetailsAntitumor peptide derived from a complementarity determining region of a humanized monoclonal antibody to NaPi2B transporter
US-9193797-B2
View Details
Immunomodulatory peptides and methods for modulating the immune system in a subject
US-11479604-B2
View DetailsAntitumor peptide derived from a complementarity determining region of a humanized monoclonal antibody to NAP12B transporter
US-9896512-B2
View DetailsAntitumor peptide derived from a complementarity determining region of a humanized monoclonal antibody to NaPi2B transporter
US-9193797-B2
View DetailsProducts
Targeted antibody-drug conjugate candidate (oncology, clinical-stage)
Antibody-based targeted therapeutic candidate developed via external ADC conjugation platforms and progressed into clinical development for solid tumors.
Clinical-stage immunomodulatory monoclonal antibodies
Monoclonal antibody candidates developed as immunomodulators/checkpoint-targeting agents and advanced into clinical trials.
Therapeutic peptide candidates
Peptide therapeutic candidates demonstrated to delay tumor progression in preclinical models and advanced through patenting and preclinical testing.
Targeted antibody-drug conjugate candidate (oncology, clinical-stage)
Antibody-based targeted therapeutic candidate developed via external ADC conjugation platforms and progressed into clinical development for solid tumors.
Clinical-stage immunomodulatory monoclonal antibodies
Monoclonal antibody candidates developed as immunomodulators/checkpoint-targeting agents and advanced into clinical trials.
Therapeutic peptide candidates
Peptide therapeutic candidates demonstrated to delay tumor progression in preclinical models and advanced through patenting and preclinical testing.
Services
Design and execution of biochemical, biophysical and functional preclinical studies (in vitro and in vivo) to assess efficacy, safety and pharmacology of antibody and peptide candidates.
Preparation of clinical protocols, regulatory registration support and management of multicenter oncology trials including site coordination across hospital networks.
Creation of stable mammalian producer cell lines and processes to support antibody production for preclinical and early clinical supply, including readiness for technology transfer to pilot manufacturing.
Immunohistochemistry and analytical assays to determine biomolecule reactivity across tissue panels and to quantify biochemical/biophysical properties.
Strategic advisory and deal execution for licensing agreements, technology transfer and collaborative R&D partnerships, including experience out-licensing clinical-stage antibody programs to international development partners.
Design and execution of biochemical, biophysical and functional preclinical studies (in vitro and in vivo) to assess efficacy, safety and pharmacology of antibody and peptide candidates.
Preparation of clinical protocols, regulatory registration support and management of multicenter oncology trials including site coordination across hospital networks.
Creation of stable mammalian producer cell lines and processes to support antibody production for preclinical and early clinical supply, including readiness for technology transfer to pilot manufacturing.
Immunohistochemistry and analytical assays to determine biomolecule reactivity across tissue panels and to quantify biochemical/biophysical properties.
Strategic advisory and deal execution for licensing agreements, technology transfer and collaborative R&D partnerships, including experience out-licensing clinical-stage antibody programs to international development partners.
Expertise Areas
- Therapeutic monoclonal antibody development
- Peptide therapeutics discovery and development
- Preclinical in vitro and in vivo pharmacology
- Clinical trial design and multicenter trial management (oncology)
Key Technologies
- Monoclonal antibody engineering
- Antibody humanization
- Antibody-drug conjugate (ADC) platform integration
- Peptide design and chemical synthesis
News & Updates
Recognition for the development of Rebmab 200, an antibody with high affinity for ovarian tumors, licensed by Recepta Biopharma.
Recepta signs an agreement to transfer rights to Agenus, related to its biopharmaceutical developments.
First Brazilian company to conduct Phase II clinical trials with monoclonal antibodies for cancer treatment
Recepta Biopharma has pioneered in conducting clinical trials for monoclonal antibodies in Brazil, with registration at ANVISA and FDA.
Development of humanized monoclonal antibodies and cell line generation
Recepta has mastered the technology of humanization and cell line development for monoclonal antibody production.
Discovery and patenting of peptides with clinical potential in cancer treatment
The company has discovered and patented peptides with potential for clinical use in oncology, verified in preclinical tests.
First licensing of a drug by a Brazilian company to a foreign company
Recepta achieved a pioneering licensing agreement for a drug developed in Brazil to an international partner.
Recognition for the development of Rebmab 200, an antibody with high affinity for ovarian tumors, licensed by Recepta Biopharma.
Recepta signs an agreement to transfer rights to Agenus, related to its biopharmaceutical developments.
First Brazilian company to conduct Phase II clinical trials with monoclonal antibodies for cancer treatment
Recepta Biopharma has pioneered in conducting clinical trials for monoclonal antibodies in Brazil, with registration at ANVISA and FDA.
Development of humanized monoclonal antibodies and cell line generation
Recepta has mastered the technology of humanization and cell line development for monoclonal antibody production.
Discovery and patenting of peptides with clinical potential in cancer treatment
The company has discovered and patented peptides with potential for clinical use in oncology, verified in preclinical tests.
First licensing of a drug by a Brazilian company to a foreign company
Recepta achieved a pioneering licensing agreement for a drug developed in Brazil to an international partner.